FAT3
FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pancreatic ductal adenocarcinoma, Renal cell carcinoma and 5 more.
Overview
May play a role in the interactions between neurites derived from specific subsets of neurons during development.
IntOGen calls it a driver in 29 cohorts (22 activating, 7 loss-of-function), covering Angiosarcoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Colon Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pancreatic ductal adenocarcinoma, Renal cell carcinoma and 5 more.
- 1 · What it is
FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pancreatic ductal adenocarcinoma, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
May play a role in the interactions between neurites derived from specific subsets of neurons during development. Location: Membrane (UniProt).
- 3 · How drugs use it
No product in this corpus aims at FAT3 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:23112 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8TDW7 (protein name, function text, keywords and locations (REST API)); IntOGen FAT3 (driver in 29 cohorts (Act 22, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
May play a role in the interactions between neurites derived from specific subsets of neurons during development. Location: Membrane (UniProt). Locus 11q14.3 (HGNC).
- Breast cancer: IntOGen driver in 4 cohorts (BRCA)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 3 cohorts (PAAD, PANCREAS)
- Renal cell carcinoma: IntOGen driver in 2 cohorts (CCRCC, RCC)
- Colorectal cancer: IntOGen driver in 2 cohorts (COAD, COADREAD)
- Prostate cancer: IntOGen driver in 2 cohorts (PRAD)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 2 cohorts (STAD, STOMACH)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 22 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 7 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FAT3" OR ABSTRACT:"FAT3" OR TITLE:"FAT atypical cadherin 3" OR ABSTRACT:"FAT atypical cadherin 3" OR TITLE:"Protocadherin Fat 3" OR ABSTRACT:"Protocadherin Fat 3" OR TITLE:"KIAA1989" OR ABSTRACT:"KIAA1989" OR TITLE:"CDHF15" OR ABSTRACT:"CDHF15" OR TITLE:"CDHR10" OR ABSTRACT:"CDHR10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAT3, not a curated reading list.